Cited by 1,088Cystic Fibrosis Research AdvancesIon Transport and Channel RegulationInhalation and Respiratory Drug Delivery

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Open access

Van Goor, Fredrick, Hadida, Sabine, Grootenhuis, Peter D. J., Burton, Bill, Stack, Jeffrey H., Straley, Kimberly S., Decker, Caroline J., Miller, Mark, McCartney, Jason, Olson, Eric R., Wine, Jeffrey J., Frizzell, Ray A., Ashlock, Melissa, Negulescu, Paul A.·2011·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1105787108PMC PMC3219147

Open this paper in CoChat — free account

Abstract

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator ( CFTR ) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs. Most patients with CF carry the F508del CFTR mutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amounts of CFTR at the cell surface. One strategy to treat these patients is to correct the processing of F508del-CFTR with small molecules. Here we describe the in vitro pharmacology of VX-809, a CFTR corrector that was advanced into clinical development for the treatment of CF. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC 50 , 81 ± 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability. VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.

Integrity signals

Registry

Crossref · 10.1073/pnas.1105787108

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,236
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225
Self-citation
Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,093
Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening
Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803
Self-citation
Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
Castellani, C., Cuppens, H., Maçek, M., Cassiman, J. J., Kerem, E., Durie, P. R., Tullis, E. D., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 624
Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening
Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 551

Show all 44 references

Research works printed but not linked: 1

; Cystic Fibrosis Foundation US Cystic Fibrosis Patient Registry (Cystic Fibrosis Foundation, Bethesda, 2002).

Sorted by citations

Items 701–800 of 1,000

The impact of personalised therapies on respiratory medicine
Elborn, J. S. (2013) · European Respiratory Review · doi:10.1183/09059180.00008212 · Cited by 9
Ivacaftor: From Bench to Bedside.. and Back Again
Molloy, K., & McElvaney, N. G. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201406-1122ed · Cited by 10
Pharmacological modulation of chloride channels as a therapeutic strategy for neurological disorders
Wang, Z., & Choi, K. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1122444 · Cited by 9
UBE3C Facilitates the ER-Associated and Peripheral Degradation of Misfolded CFTR
Kamada, Y., Tateishi, H., Nakayamada, U., Hinata, D., Iwasaki, A., Zhu, J., Fukuda, R., & Okiyoneda, T. (2023) · Cells · doi:10.3390/cells12232741 · Cited by 9
Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study
Kim, C., Higgins, M., Liu, L., Volkova, N. V., Zolin, A., Naehrlich, L., Andreas, P., Elise, L. (., Duška, T.-D., Pavel, D. (., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.02.004 · Cited by 9
Characterization of Δ(G970-T1122)-CFTR, the most frequent CFTR mutant identified in Japanese cystic fibrosis patients
Wakabayashi‐Nakao, K., Yu, Y., Nakakuki, M., Hwang, T., Ishiguro, H., & Sohma, Y. (2018) · The Journal of Physiological Sciences · doi:10.1007/s12576-018-0626-4 · Cited by 9
S945L-CFTR molecular dynamics, functional characterization and tezacaftor/ivacaftor efficacy in vivo and in vitro in matched pediatric patient-derived cell models
Allan, K. M., Astore, M. A., Fawcett, L. K., Wong, S. L., Chen, P., Griffith, R., Jaffé, A., Kuyucak, S., & Waters, S. A. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.1062766 · Cited by 9
The expression system influences stability, maturation efficiency, and oligomeric properties of the potassium-chloride co-transporter KCC2
Kok, M., Hartnett, K. A., Happe, C. L., MacDonald, M. L., Aizenman, E., & Brodsky, J. L. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105695 · Cited by 9
Genetics of pancreatitis with a focus on the pancreatic ducts.
LaRusch, J., & Whitcomb, D. C. (2012) · PubMed · Cited by 9
On the interactions between nucleotide binding domains and membrane spanning domains in cystic fibrosis transmembrane regulator: A molecular dynamic study
Belmonte, L., & Morán, Ó. (2015) · Biochimie · doi:10.1016/j.biochi.2015.01.010 · Cited by 9
A new Era of Personalized Medicine for Cystic Fibrosis – at Last!
Quon, B. S., & Wilcox, P. (2015) · Canadian Respiratory Journal · doi:10.1155/2015/921712 · Cited by 9
c.3623G > A mutation encodes a CFTR protein with impaired channel function
Zhang, X., Hothi, J. S., Zhang, Y. H., Srinivasan, S., Stokes, D. C., & Zhang, W. (2016) · Respiratory Research · doi:10.1186/s12931-016-0326-7 · Cited by 9
Antiestrogen- and tamoxifen-induced effects on calcium-activated chloride currents in epithelial cells carrying the ∆F508-CFTR point mutation
Imberti, R., Garavaglia, M. L., Verduci, I., Cannavale, G., Balduzzi, G., Papetti, S., & Mazzanti, M. (2018) · Respiratory Research · doi:10.1186/s12931-018-0901-1 · Cited by 9
S -Nitrosylation of CHIP Enhances F508Del-CFTR Maturation
Zaman, K., Knight, J. C., Hussain, F., Cao, R., Estabrooks, S. K., Altawallbeh, G., Holloway, K., Jafri, A., Sawczak, V., Li, Y., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0314oc · Cited by 9
What Is the Potential for Lumacaftor as a Chemical Chaperone in Promoting hERG Trafficking?
Zheng, Z., Song, Y., & Lian, J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.801927 · Cited by 9
Established and novel human translational models to advance cystic fibrosis research, drug discovery, and optimize CFTR-targeting therapeutics
Cholon, D. M., & Gentzsch, M. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102210 · Cited by 10
Self-Reactive CFTR T Cells in Humans: Implications for Gene Therapy
Calcedo, R., Uta Griesenbach, D., Dorgan, D. J., Soussi, S., Boyd, A., Davies, J. C., Higgins, T., Hyde, S. C., Gill, D. R., Innes, J. A., et al. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2012.249 · Cited by 9
Pharmacogenetics of Cystic Fibrosis Treatment
Carter, S. C., & McKone, E. F. (2016) · Pharmacogenomics · doi:10.2217/pgs.16.25 · Cited by 9
Direct Measurement of Trafficking of the Cystic Fibrosis Transmembrane Conductance Regulator to the Cell Surface and Binding to a Chemical Chaperone
Zhang, Z., Baksh, M. M., Finn, M. G., Heidary, D. K., & Richards, C. I. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00853 · Cited by 9
Activation of Endoplasmic Reticulum Stress and Unfolded Protein Response in Congenital Factor VII Deficiency
Andersen, E. W., Chollet, M. E., Myklebust, C. F., Pinotti, M., Bernardi, F., Chuansumrit, A., Skarpen, E., Sandset, P. M., & Skretting, G. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1637690 · Cited by 9
Emerging pharmacotherapies in cystic fibrosis
McElvaney, O. J., Gunaratnam, C., McElvaney, O. F., Bagwe, I., Reeves, E. P., & McElvaney, N. G. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1512409 · Cited by 9
Chronic ivacaftor treatment: Getting F508del-CFTR into more trouble?
Mall, M. A., & Sheppard, D. N. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.10.001 · Cited by 9
Assessing the Potential of N-Butyl- l -deoxynojirimycin ( l -NBDNJ) in Models of Cystic Fibrosis as a Promising Antibacterial Agent
Esposito, A., Rossi, A., Stabile, M. R., Pinto, G., Fino, I. D., Melessike, M., Tamanini, A., Cabrini, G., Lippi, G., Aureli, M., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00044 · Cited by 8
The potentiator ivacaftor is essential for pharmacological restoration of F508del-CFTR function and mucociliary clearance in cystic fibrosis
Balázs, A., Rubil, T., Wong, C. K., Berger, J., Drescher, M., Seidel, K., Stahl, M., Graeber, S. Y., & Mall, M. A. (2025) · JCI Insight · doi:10.1172/jci.insight.187951 · Cited by 9
Integrating Viral and Nonviral Vectors for Cystic Fibrosis Gene Therapy in the Airways
Cooney, A. L., McCray, P. B., & Sinn, P. L. (2015) · InTech eBooks · doi:10.5772/60977 · Cited by 9
c-Cbl reduces stability of rescued ∆F508-CFTR in human airway epithelial cells
Cihil, K. M., Zimnik, A. J., & Swiatecka‐Urban, A. (2013) · Communicative & Integrative Biology · doi:10.4161/cib.23094 · Cited by 8
Readthrough-induced misincorporated amino acid ratios guide mutant-specific therapeutic approaches for two CFTR nonsense mutations
Premchandar, A., Ming, R., Baiad, A. A., Fonte, D. F. D., Xu, H., Faubert, D., Veit, G., & Lukács, G. L. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1389586 · Cited by 8
Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis
Barreca, M., Renda, M., Spanò, V., Montalbano, A., Raimondi, M. V., Giuffrida, S., Bivacqua, R., Bandiera, T., Galietta, L. J. V., & Barraja, P. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116691 · Cited by 8
ABC transporters involved in respiratory and cholestatic diseases: From rare to very rare monogenic diseases
Lakli, M., Onnée, M., Carrez, T., Becq, F., Falguières, T., & Fanen, P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116468 · Cited by 11
Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions
Uliyakina, I., Paula, A. C. D., Afonso, S., Lobo, M. J., Felício, V., Botelho, H. M., Farinha, C. M., & Amaral, M. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124524 · Cited by 8
Phenotypic Drug Discovery: History, Evolution, Future
Swinney, D. C. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721-00001 · Cited by 7
Improved repeatability of nasal potential difference with a larger surface catheter
Vermeulen, F. L., Proesmans, M., Boon, M., & Boeck, K. D. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.08.006 · Cited by 8
Generation of ΔF508-CFTR T84 cell lines by CRISPR/Cas9-mediated genome editing
Chung, W. Y., Song, M., Park, J., Namkung, W., Lee, J., Kim, S., Lee, M. G., & Kim, J. Y. (2016) · Biotechnology Letters · doi:10.1007/s10529-016-2190-4 · Cited by 8
Novel and Experimental Therapies in Chronic Pancreatitis
Jagannath, S., & Garg, P. K. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4604-0 · Cited by 8
Bioactive Thymosin Alpha-1 Does Not Influence F508del-CFTR Maturation and Activity
Armirotti, A., Tomati, V., Matthes, E., Veit, G., Cholon, D. M., Phuan, P., Braccia, C., Guidone, D., Gentzsch, M., Lukács, G. L., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46639-1 · Cited by 8
How to Avoid a No-Deal ER Exit
Anelli, T., & Panina‐Bordignon, P. (2019) · Cells · doi:10.3390/cells8091051 · Cited by 8
Identification of Compounds That Promote Readthrough of Premature Termination Codons in the CFTR
Smith, E. W., Dukovski, D., Shumate, J., Scampavia, L. D., Miller, J. P., & Spicer, T. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220962001 · Cited by 8
Cystic fibrosis two-step
Cain, C. (2012) · Science-Business eXchange · doi:10.1038/scibx.2012.192 · Cited by 8
Congenital hypothyroidism mutations affect common folding and trafficking in the α/β‐hydrolase fold proteins
Jaco, A. D., Dubi, N., Camp, S., & Taylor, P. (2012) · FEBS Journal · doi:10.1111/febs.12019 · Cited by 8
Repurposing therapies for the personalised treatment of cystic fibrosis
Tosco, A., Villella, V. R., Castaldo, A., Kroemer, G., Maiuri, L., & Raia, V. (2018) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1483231 · Cited by 7
Diagnosis and treatment of cystic fibrosis in India: What is at stake for developing countries?
Purushothaman, A. K., Natarajan, S., Panigrahi, T., & Nelson, E. J. R. (2024) · Journal of Biosciences · doi:10.1007/s12038-024-00456-5 · Cited by 7
The holy grail of cystic fibrosis research: pharmacological repair of the F508del-CFTR mutation.
Maiuri, L., Stefano, D. D., Raia, V., & Kroemer, G. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.02.32 · Cited by 7
Mechanistic insight into the heme-independent interplay between iron and carbon monoxide in CFTR and Slo1 BKCa channels
Wang, G. (2017) · Metallomics · doi:10.1039/c7mt00065k · Cited by 7
F508del-CFTR is not corrected by thymosin α1
Matthes, E., Hanrahan, J. W., & Cantin, A. M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0079-6 · Cited by 7
Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
Pohl, K., Nichols, D. P., Taylor‐Cousar, J. L., Saavedra, M. T., Strand, M. J., Nick, J. A., & Bratcher, P. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209026 · Cited by 8
Protein destabilization and degradation as a mechanism for hereditary disease
Nielsen, S. V., Schenstrøm, S. M., Christensen, C. E., Stein, A., Lindorff‐Larsen, K., & Hartmann‐Petersen, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819132-3.00006-3 · Cited by 8
Computational analysis of androgen receptor (AR) variants to decipher the relationship between protein stability and related-diseases
Chen, F., Chen, X., Jiang, F., Leng, F., Liu, W. Y., Gui, Y., & Yu, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-68731-7 · Cited by 7
Surfactant protein C mutations and familial pulmonary fibrosis: stuck in a loop on the scenic route
Gooptu, B. (2022) · European Respiratory Journal · doi:10.1183/13993003.02147-2021 · Cited by 7
Controlling ion channel function with renewable recombinant antibodies
Colecraft, H. M., & Trimmer, J. S. (2022) · The Journal of Physiology · doi:10.1113/jp282403 · Cited by 6
Intracellular Delivery of Peptidyl Ligands by Reversible Cyclization: Discovery of a PDZ Domain Inhibitor that Rescues CFTR Activity
Qian, Z., Xu, X., Amacher, J. F., Madden, D. R., Cormet‐Boyaka, E., & Pei, D. (2015) · Angewandte Chemie · doi:10.1002/ange.201411594 · Cited by 7
Cystic fibrosis transmembrane regulator correction attenuates heart failure-induced lung inflammation
Uhl, F. E., Vanherle, L., & Meißner, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.928300 · Cited by 7
Current Practices in Pharmacogenomics
Ramsey, L. B., Prows, C. A., Girdwood, S. T., & Driest, S. L. V. (2023) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2023.05.010 · Cited by 7
A comprehensive review on the current status of CRISPR based clinical trials for rare diseases
Badwal, A. K., & Singh, S. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.134097 · Cited by 10
Efficacy and adverse effects of drugs used to treat adult cystic fibrosis
Chopra, R., Paul, L., Manickam, R., Aronow, W. S., & Maguire, G. P. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.994503 · Cited by 7
Rescuing ΔF508 CFTR with trimethylangelicin, a dual-acting corrector and potentiator
Collawn, J. F., Fu, L., Bartoszewski, R., & Matalon, S. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00177.2014 · Cited by 7
Precise treatment of cystic fibrosis – current treatments and perspectives for using CRISPR
Colemeadow, J., Joyce, H., & Turcanu, V. (2016) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2016.1146077 · Cited by 8
CFTR and Cystic Fibrosis
Harris, W. T., & Kirk, K. L. (2015) · Springer eBooks · doi:10.1007/978-1-4939-3366-2_16 · Cited by 7
Targeted therapy for chronic respiratory disease: a new paradigm
Gibson, P. G., Peters, M. J., & Wainwright, C. E. (2017) · The Medical Journal of Australia · doi:10.5694/mja16.00731 · Cited by 7
ΔF508-CFTR Modulator Screen Based on Cell Surface Targeting of a Chimeric Nucleotide Binding Domain 1 Reporter
Phuan, P., Veit, G., Tan, J., Roldán, A., Finkbeiner, W. E., Haggie, P. M., Lukács, G. L., & Verkman, A. S. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218763310 · Cited by 7
Fluorescence assay for simultaneous quantification of CFTR ion-channel function and plasma membrane proximity
Prins, S., Langron, E., Hastings, C., Hill, E. J., Stefan, A. C., Griffin, L. D., & Vergani, P. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014061 · Cited by 7
Cholinesterase confabs and cousins: Approaching forty years
Taylor, P., Jaco, A. D., Comoletti, D., Miller, M. T., & Camp, S. (2012) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2012.10.004 · Cited by 7
Self-citation
A Homogeneous Cell-Based Halide-Sensitive Yellow Fluorescence Protein Assay to Identify Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Ion Channel
Smith, E. W., Giuliano, K. A., Shumate, J., Baillargeon, P., McEwan, B., Cullen, M. D., Miller, J. P., Drew, L., Scampavia, L. D., & Spicer, T. (2017) · Assay and Drug Development Technologies · doi:10.1089/adt.2017.810 · Cited by 7
Light‐Enabled [2 σ + 2 π ] Cycloadditions of Bicyclo[1.1.0]butanes and Alkenes by Ti‐Salen Photocatalysis
Xing, J., Li, D., Li, T., Xu, Y., Ren, H., & Zheng, J. (2025) · ChemistryEurope · doi:10.1002/ceur.202500139 · Cited by 6
Inhibitors of the ubiquitin‑proteasome system rescue cellular levels and ion transport function of pathogenic pendrin (SLC26A4) protein variants
Bernardinelli, E., Jamontas, R., Matulevičius, A., Huber, F., Nasser, H., Klaus, S., Zhu, H., Gao, J., & Dossena, S. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5510 · Cited by 6
AAV1-CFTR preferentially transduces cysts and reduces cyst size in a mouse model of ADPKD
Ciobanu, C., & Cebotaru, L. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00057.2025 · Cited by 6
Influence of SNPs in Genes that Modulate Lung Disease Severity in a Group of Mexican Patients with Cystic Fibrosis
Yokoyama, E., Chávez‐Saldaña, M., Orozco, L., Cuevas, F., Lezana, J. L., Vigueras‐Villaseñor, R. M., Rojas‐Castañeda, J. C., & Landero‐Huerta, D. A. (2018) · Archives of Medical Research · doi:10.1016/j.arcmed.2018.04.010 · Cited by 6
Emerging medicines to improve the basic defect in cystic fibrosis
Fajac, I., & Sermet‐Gaudelus, I. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2092612 · Cited by 6
Pharmacological chaperone-rescued cystic fibrosis CFTR-F508del mutant overcomes PRAF2-gated access to endoplasmic reticulum exit sites
Saha, K., Chevalier, B., Doly, S., Baatallah, N., Guilbert, T., Pranke, I. M., Scott, M. G. H., Enslen, H., Guerrera, I. C., Chuon, C., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04554-1 · Cited by 6
Synthesis and Evaluation of Ivacaftor Derivatives with Reduced Lipophilicity
Iazzi, M., Junor, P., Doshi, J., Acharya, S., Sühring, R., Viirre, R. D., & Gupta, G. D. (2023) · ACS Omega · doi:10.1021/acsomega.3c05839 · Cited by 6
Cystic Fibrosis Bronchial Epithelial Cells Are Lipointoxicated by Membrane Palmitate Accumulation
Payet, L.-A., Kadri, L., Giraud, S., Norez, C., Berjeaud, J., Jayle, C., Mirval, S., Becq, F., Vandebrouck, C., & Ferreira, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089044 · Cited by 6
Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis
Pesce, E., Pedemonte, N., Leoni, A., Locatelli, A., & Morigi, R. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127473 · Cited by 6
Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors
Saint‐Criq, V., Wang, Y., Delpiano, L., Lin, J., Sheppard, D. N., & Gray, M. A. (2021) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2021.04.013 · Cited by 6
CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
de Poel, E., Spelier, S., Korporaal, R., Lai, K. W., Boj, S. F., Conrath, K., van der Ent, C. K., & Beekman, J. M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.698358 · Cited by 6
Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis
Williamson, M., Casey, M., Gabillard-Lefort, C., Alharbi, A., Teo, Y. Q. J., McElvaney, N. G., & Reeves, E. P. (2021) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2021.2001333 · Cited by 6
The multiple ubiquitination mechanisms in CFTR peripheral quality control
Taniguchi, S., Fukuda, R., & Okiyoneda, T. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221468 · Cited by 6
Genotype-specific small-molecule therapy for cystic fibrosis
Thursfield, R., & Davies, J. C. (2013) · Breathe · doi:10.1183/20734735.039212 · Cited by 6
PharmGKB summary
McDonagh, E. M., Clancy, J. P., Altman, R. B., & Klein, T. E. (2014) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000112 · Cited by 6
Mutation-specific therapies and drug repositioning in cystic fibrosis
Villella, V. R., Tosco, A., Esposito, S., Bona, G., Raia, V., & Maiuri, L. (2019) · Minerva Pediatrics · doi:10.23736/s0026-4946.19.05506-3 · Cited by 6
Differential scanning fluorimetry in the screening and validation of pharmacological chaperones for soluble and membrane proteins
Støve, S. I., Flydal, M. I., Hausvik, E., Underhaug, J., & Martı́nez, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819132-3.00015-4 · Cited by 6
Relax, Cool Down and Scaffold: How to Restore Surface Expression of Folding-Deficient Mutant GPCRs and SLC6 Transporters
Asjad, H. M. M., Nasrollahi-Shirazi, S., Sučić, S., Freissmuth, M., & Nanoff, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112416 · Cited by 6
Response to: ‘Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?’ by Jones and Barry
Elborn, J. S., Ramsey, B. W., Wainwright, C. E., & Boyle, M. (2015) · Thorax · doi:10.1136/thoraxjnl-2015-207611 · Cited by 6
CFTR Modulators Counteract F508del CFTR Functional Defects in a Pancreatic Epithelial Model of Cystic Fibrosis
Ludovico, A., & Baroni, D. (2025) · Life · doi:10.3390/life15081315 · Cited by 6
Therapeutics in Metabolic Diseases
Natesan, V. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_17 · Cited by 5
Ligand-based virtual-screening identified a novel CFTR ligand which improves the defective cell surface expression of misfolded ABC transporters
Taniguchi, S., Berenger, F., Doi, Y., Mimura, A., Yamanishi, Y., & Okiyoneda, T. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1370676 · Cited by 5
A cell-permeable nanobody to restore F508del cystic fibrosis transmembrane conductance regulator activity
Franz, L., Rubil, T., Balázs, A., Overtus, M., Kemnitz‐Hassanin, K., Govaerts, C., Mall, M. A., & Hackenberger, C. P. R. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02199-w · Cited by 6
Introduction of Ivacaftor/Lumacaftor in Children With Cystic Fibrosis Homozygous for F508del in the Netherlands: A Nationwide Real‐Life Study
Zwitserloot, A. M., Aziz, S. Z., Chen, Y., Bannier, M. A. G. E., Janssens, H. M., Merkus, P. J. F. M., Nuijsink, M., Terheggen‐Lagro, S. W. J., Tiddens, H. A. W. M., Ommen, D. D. Z.-V., et al. (2025) · Pediatric Pulmonology · doi:10.1002/ppul.27473 · Cited by 5
In silico , in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators
Pesce, E., Tomati, V., Capurro, V., Lena, M., Pastorino, C., Astore, M. A., Kuyucak, S., Chevalier, B., Sondo, E., Cresta, F., et al. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70176 · Cited by 4
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays
Parodi, A. C. L., Righetti, G., Pesce, E., Salis, A., Tomati, V., Pastorino, C., Tasso, B., Benvenuti, M., Damonte, G., Pedemonte, N., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15030274 · Cited by 5
KCa3.1 potentiation stimulates Cl− secretion in F508del and G551D CFTR-corrected primary human bronchial epithelial cells
Devor, D. C., Green, M. D., & Bridges, R. J. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00319.2022 · Cited by 5
Biochemical characterization of two novel mutations in the human high-affinity choline transporter 1 identified in a patient with congenital myasthenic syndrome
Rizvi, M., Truong, T. K., Zhou, J. R., Batta, M., Moran, E. S., Pappas, J., Chu, M. L., Caluseriu, O., Evrony, G. D., Leslie, E. M., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddac309 · Cited by 5
Pharmacological inhibition of CFTR attenuates nonalcoholic steatohepatitis (NASH) progression in mice
Rajak, S., Tewari, A., Raza, S., Gupta, P., Chakravarti, B., Anjum, B., Tripathi, M., Singh, B. K., Yen, P. M., Goel, A., et al. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2023.166662 · Cited by 5
Mucoviscidose : l’espace bleu entre les nuages ?
Léonard, A., Leal, T., & Lebecque, P. (2013) · Archives de Pédiatrie · doi:10.1016/j.arcped.2012.10.018 · Cited by 5
Cystic fibrosis in the era of genomic medicine
Milla, C. E. (2013) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e328360dbf5 · Cited by 5
CFTR Potentiators: Not an Open and Shut Case
Clancy, J. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009674 · Cited by 5
New drug developments in the management of cystic fibrosis lung disease
Turnbull, A. R., & Davies, J. C. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1157582 · Cited by 5
Nouvelles thérapeutiques ciblant le canal chlorure dans la mucoviscidose
Bui, S., Macey, J., Fayon, M. J., Bihouée, T., Burgel, P., Colomb, V., Corvol, H., Durieu, I., Hubert, D., Marguet, C., et al. (2016) · Archives de Pédiatrie · doi:10.1016/s0929-693x(17)30062-3 · Cited by 5
Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
Shiferaw, D., & Faruqi, S. (2019) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s165027 · Cited by 5
Gene Therapy in Cystic Fibrosis
Prickett, M. H., & Jain, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800563-7.00016-6 · Cited by 5
Ethical Dilemma
Breuer, O., Shoseyov, D., Koretz, S., Alyan, N., Reiter, J. M., Cohen‐Cymberknoh, M., Wexler, I. D., & Kerem, E. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.08.073 · Cited by 6
CFTR and Cystic Fibrosis: A Need for Personalized Medicine
Bradbury, N. A. (2020) · Physiology in health and disease · doi:10.1007/978-3-030-55454-5_15 · Cited by 5

Authors: Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., Wine, J. J., Frizzell, R. A., Ashlock, M., & Negulescu, P. A.
Affiliations: Vertex Pharmaceuticals, San Diego, CA 92121;
Vertex Pharmaceuticals (United States) (US)
Stanford University (US)
Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261; and
Cystic Fibrosis Foundation (US)
Corresponding author: Negulescu, Paul A.
ORCID: Miller, Mark
Olson, Eric R.
Wine, Jeffrey J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2011-10-05
Volume: 108
Issue: 46
Pages: 18843-18848
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1105787108
PMC: PMC3219147
OpenAlex: W2071407356
Cited by: 1,088
References: 44
Citations by year: 2026: 24 · 2025: 48 · 2024: 48 · 2023: 57 · 2022: 64 · 2021: 83 · 2020: 98 · 2019: 95 · 2018: 101 · 2017: 103 · 2016: 77 · 2015: 85 · 2014: 84 · 2013: 61 · 2012: 58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Cystic Fibrosis Foundation Therapeutics
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords: cystic fibrosis, F508del-CFTR, CFTR correctors, lumacaftor, endoplasmic reticulum retention, chloride secretion, bronchial epithelial cells, CFTR mutations
MeSH terms: Aminopyridines, Bronchi, Cell Line, Cells, Cultured, Chemistry, Pharmaceutical, Chlorides, Cystic Fibrosis, Drug Evaluation, Preclinical, Epithelial Cells, Homozygote, Humans, Lung, Models, Genetic, Mutation, Drug Design, Cystic Fibrosis Transmembrane Conductance Regulator, Benzodioxoles, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks